Compare AMTX & XTNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMTX | XTNT |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.6M | 86.2M |
| IPO Year | 2023 | 2009 |
| Metric | AMTX | XTNT |
|---|---|---|
| Price | $1.42 | $0.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.00 | $1.50 |
| AVG Volume (30 Days) | ★ 828.2K | 133.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $77,194,000.00 | $53,337,000.00 |
| Revenue This Year | N/A | $15.08 |
| Revenue Next Year | $139.04 | N/A |
| P/E Ratio | ★ N/A | $19.28 |
| Revenue Growth | ★ 174.60 | N/A |
| 52 Week Low | $1.22 | $0.34 |
| 52 Week High | $3.66 | $0.95 |
| Indicator | AMTX | XTNT |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 37.95 |
| Support Level | $1.38 | $0.55 |
| Resistance Level | $1.65 | $0.66 |
| Average True Range (ATR) | 0.08 | 0.03 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.63 | 20.04 |
Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.